Fulcrum expects ~$240M cash at year-end 2024 (preliminary)

Fulcrum Therapeutics, Inc.

Expects approximately $240M in cash, equivalents and marketable securities as of Dec 31, 2024 (preliminary, unaudited).
Full Q4 and FY2024 financial results not yet finalized; audit ongoing.
Updated corporate presentation published on January 13, 2025 on company website.

item 2.02 item 7.01 item 9.01

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-004942

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.